152 related articles for article (PubMed ID: 10432950)
81. [Anticoagulant].
Mitome J; Yamamoto H
Nihon Rinsho; 2004 May; 62 Suppl 5():368-73. PubMed ID: 15197947
[No Abstract] [Full Text] [Related]
82. Direct thrombin inhibitors in patients with mechanical heart valves: ready for clinical trials?
Rupprecht HJ
Thromb Haemost; 2009 Jun; 101(6):995-6. PubMed ID: 19492137
[No Abstract] [Full Text] [Related]
83. Haemofiltration/haemodialysis in patients with heparin-associated thrombocytopenia.
Chong BH; Jacques T
Intensive Care Med; 1991; 17(7):437. PubMed ID: 1774405
[No Abstract] [Full Text] [Related]
84. [Heparin-induced thrombocytopenia].
Greinacher A
Wien Klin Wochenschr; 1997 May; 109(10):343-5. PubMed ID: 9265384
[No Abstract] [Full Text] [Related]
85. Bilateral adrenal hemorrhages in a patient with heparin-induced thrombocytopenia.
Montealegre-Gallegos M; Bose S
CMAJ; 2019 Nov; 191(44):E1222. PubMed ID: 31685666
[No Abstract] [Full Text] [Related]
86. Eczematous plaques related to unfractionated and low-molecular-weight heparin in pregnancy: cross-reaction with danaparoid sodium.
Blickstein D; Hod M; Bar J
Blood Coagul Fibrinolysis; 2003 Dec; 14(8):765-8. PubMed ID: 14614358
[TBL] [Abstract][Full Text] [Related]
87. Danaparoid reduces the incidence of hematopoietic stem cell transplantation-associated thrombotic microangiopathy.
Machida S; Onizuka M; Toyosaki M; Aoyama Y; Kawai H; Amaki J; Hara R; Ichiki A; Ogawa Y; Kawada H; Ando K
Bone Marrow Transplant; 2017 Feb; 52(2):307-309. PubMed ID: 27892947
[No Abstract] [Full Text] [Related]
88. Evidence for a locally limited form of heparin-induced thrombocytopenia in plastic reconstructive surgery?
Busch KH; Knobloch K; Vogt PM
Plast Reconstr Surg; 2009 Nov; 124(5):277e-278e. PubMed ID: 20009819
[No Abstract] [Full Text] [Related]
89. Effect of combined therapy of danaparoid sodium and tranexamic acid on chronic disseminated intravascular coagulation associated with abdominal aortic aneurysm.
Ontachi Y; Asakura H; Arahata M; Kadohira Y; Maekawa M; Hayashi T; Yamazaki M; Morishita E; Saito M; Minami S; Nakao S
Circ J; 2005 Sep; 69(9):1150-3. PubMed ID: 16127203
[TBL] [Abstract][Full Text] [Related]
90. Effect of danaparoid sodium on proteinuria, von Willebrand factor, and hard exudates in patients with diabetes mellitus type 2.
van der Pijl JW; Lemkes HH; Frölich M; van der Woude FJ; van der Meer FJ; Van Es LA
J Am Soc Nephrol; 1999 Jun; 10(6):1331-6. PubMed ID: 10361873
[TBL] [Abstract][Full Text] [Related]
91. Heparin-induced thrombocytopenia and warfarin-induced skin necrosis in a child with severe protein C deficiency: successful treatment with dermatan sulfate and protein C concentrate.
Gatti L; Carnelli V; Rusconi R; Moia M
J Thromb Haemost; 2003 Feb; 1(2):387-8. PubMed ID: 12871519
[No Abstract] [Full Text] [Related]
92. Dermatan sulphate in heparin-induced thrombocytopenia.
Agnelli G; Iorio A; de Angelis V; Nenci GG
Lancet; 1994 Nov; 344(8932):1295-6. PubMed ID: 7968002
[No Abstract] [Full Text] [Related]
93. Successful treatment with dermatan sulfate in six patients with heparin-induced thrombocytopenia and acute venous thromboembolism.
Imberti D; Verso M; Silvestrini E; Taliani MR; Agnelli G
J Thromb Haemost; 2003 Dec; 1(12):2696-7. PubMed ID: 14675116
[No Abstract] [Full Text] [Related]
94. Treatment dosage recommendation for fondaparinux in a patient with heparin induced thrombocytopenia.
Fulco PP
J Thromb Thrombolysis; 2006 Aug; 22(1):69. PubMed ID: 16786235
[No Abstract] [Full Text] [Related]
95. Heparin-induced thrombocytopenia: pathogenesis and management.
Saad RA
Br J Haematol; 2003 Oct; 123(2):373-4; author reply 374. PubMed ID: 14531929
[No Abstract] [Full Text] [Related]
96. Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety.
Hirsh J; Raschke R; Warkentin TE; Dalen JE; Deykin D; Poller L
Chest; 1995 Oct; 108(4 Suppl):258S-275S. PubMed ID: 7555181
[No Abstract] [Full Text] [Related]
97. Glycosaminoglycans are a potential cause of rheumatoid arthritis.
Wang JY; Roehrl MH
Proc Natl Acad Sci U S A; 2002 Oct; 99(22):14362-7. PubMed ID: 12391302
[TBL] [Abstract][Full Text] [Related]
98. Managing heparin infusions.
Brown NF; Bart-Smith E; Gillett D
Br J Hosp Med (Lond); 2012 Jun; 73(6):C85-8. PubMed ID: 22875274
[No Abstract] [Full Text] [Related]
99. Tainted heparin crisis tested FDA's investigative skills.
Lavine G
Am J Health Syst Pharm; 2009 Feb; 66(3):210-1. PubMed ID: 19179633
[No Abstract] [Full Text] [Related]
100. From crisis to opportunity: a perspective on the heparin crisis.
Sasisekharan R; Shriver Z
Thromb Haemost; 2009 Nov; 102(5):854-8. PubMed ID: 19888519
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
